| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1146/ANNUREV.PHARMTOX.43.100901.140226 |
| P698 | PubMed publication ID | 12540742 |
| P50 | author | Louis Ignarro | Q309820 |
| Claudio Napoli | Q37836844 | ||
| P2860 | cites work | Nitric oxide-releasing polymers containing the [N(O)NO]- group | Q71176213 |
| Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion | Q71705751 | ||
| Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in rats | Q72988530 | ||
| Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs | Q73044812 | ||
| IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs | Q73112975 | ||
| Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs | Q73126827 | ||
| Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial | Q73176018 | ||
| HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease | Q73176738 | ||
| Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway | Q73470859 | ||
| Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability | Q73566757 | ||
| Coronary stenosis dilatation induced by L-arginine | Q73620129 | ||
| Effect of L-arginine administration on myocardial thallium-201 perfusion during exercise in patients with angina pectoris and normal coronary angiograms | Q73745441 | ||
| Oral L-arginine in patients with coronary artery disease on medical management | Q73762604 | ||
| Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin | Q73871242 | ||
| Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase | Q73935065 | ||
| Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina | Q74012776 | ||
| Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils | Q74065465 | ||
| Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats | Q74307016 | ||
| Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys | Q74314793 | ||
| Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells | Q74449503 | ||
| Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans | Q74645901 | ||
| Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide | Q74845860 | ||
| Nitric oxide and its role in apoptosis | Q77164340 | ||
| The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces | Q77291990 | ||
| Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats | Q77374986 | ||
| Effects of changing the availability of the substrate for nitric oxide synthase by L-arginine administration on coronary vasomotor tone in angina patients with angiographically narrowed and in patients with normal coronary arteries | Q77562799 | ||
| Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial | Q77651675 | ||
| Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris | Q77769400 | ||
| A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA | Q77854970 | ||
| Plasma alpha-tocopherol and coronary endothelium-dependent vasodilator function | Q78017102 | ||
| Aspirin: new cardiovascular uses for an old drug | Q28175524 | ||
| Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat | Q28181456 | ||
| Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats | Q28187870 | ||
| NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes | Q28190347 | ||
| Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation | Q28205767 | ||
| Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque | Q28346458 | ||
| Overall cardiovascular profile of sildenafil citrate | Q28371743 | ||
| Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability | Q28378468 | ||
| Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells | Q28379577 | ||
| Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate | Q28569170 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment | Q30861585 | ||
| Interactions among ACE, kinins and NO. | Q33179836 | ||
| Endothelial dysfunction: from physiology to therapy | Q33540189 | ||
| Pathophysiology of nitric oxide and related species: free radical reactions and modification of biomolecules | Q33610044 | ||
| The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals | Q33688733 | ||
| NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. | Q33702264 | ||
| Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide | Q33736243 | ||
| Nitric oxide as a signaling molecule in the vascular system: an overview. | Q33794569 | ||
| On the role of vitamin C and other antioxidants in atherogenesis and vascular dysfunction | Q33796813 | ||
| Vitamin E and heart disease: basic science to clinical intervention trials | Q33828621 | ||
| Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. | Q33835861 | ||
| Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials | Q33848201 | ||
| Aspirin. | Q33861695 | ||
| Nitric oxide (NO)-related pharmaceuticals: contemporary approaches to therapeutic NO modulation | Q33991778 | ||
| Local drug delivery: an emerging approach in the treatment of restenosis | Q34004350 | ||
| Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. | Q34010668 | ||
| Sodium nitroprusside: twenty years and counting | Q34058143 | ||
| Nitric oxide donors | Q34084629 | ||
| Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis? | Q34086712 | ||
| In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. | Q34188808 | ||
| Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance | Q34194262 | ||
| Atherogenesis and the arginine hypothesis | Q34207440 | ||
| Nitric oxide and atherosclerosis | Q34211736 | ||
| S-nitrosothiols do not induce oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells | Q43774256 | ||
| Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering | Q43869277 | ||
| Long-term treatment with nipradilol, a nitric oxide-releasing beta-adrenergic blocker, enhances postischemic recovery and limits infarct size | Q43880096 | ||
| Involvement of nitric oxide in the ocular hypotensive action of nipradilol | Q43929182 | ||
| Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure | Q43940514 | ||
| Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide | Q44000686 | ||
| Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure | Q44283902 | ||
| Nitric oxide donors increase mucus gel thickness in rat stomach. | Q44975025 | ||
| The effect of aspirin and two nitric oxide donors on the infarcted heart in situ | Q45301125 | ||
| Selective COX-2 inhibitors: are they safe for the stomach? | Q47899828 | ||
| Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity | Q47899971 | ||
| In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. | Q50751608 | ||
| Nebivolol Induces Endothelium Dependent Relaxatíons of Canine Coronary Arteries | Q50803619 | ||
| Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite possible involvement of S-nitrosothiols | Q50942819 | ||
| Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats. | Q51506576 | ||
| A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. | Q54185003 | ||
| Editorials | Q57589089 | ||
| NO-aspirin protects from T cell–mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines | Q58855408 | ||
| Mildly Oxidized Low-Density Lipoprotein Impairs Responses of Carotid but Not Basilar Artery in Rabbits | Q58863686 | ||
| In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016 | Q60695438 | ||
| Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions | Q61053089 | ||
| Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine | Q68326802 | ||
| Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) | Q71060539 | ||
| Nitric oxide mediated venodilator effects of nebivolol | Q34346253 | ||
| Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone | Q34378188 | ||
| Nitric oxide: not just a negative inotrope | Q34398226 | ||
| Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
| Inhaled nitric oxide in cardiology | Q34481821 | ||
| Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview | Q34489991 | ||
| Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice | Q34500809 | ||
| Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. | Q34506235 | ||
| The role of nitric oxide in tissue destruction | Q34506564 | ||
| Oxidation-sensitive transcription factors and molecular mechanisms in the arterial wall. | Q34507734 | ||
| N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin | Q34548644 | ||
| Nitroprusside-related cyanide poisoning. Time (long past due) for urgent, effective interventions | Q35535909 | ||
| L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans | Q35606367 | ||
| Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide | Q35767797 | ||
| Role of nitrates in acute myocardial infarction | Q35858186 | ||
| The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension | Q36053698 | ||
| Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase | Q36225423 | ||
| S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds | Q36780079 | ||
| Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug | Q37359995 | ||
| Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions | Q37375378 | ||
| Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein e knockout mice but not in C57BL/6 mice | Q37401587 | ||
| Biocompatibility aspects of new stent technology | Q38550109 | ||
| The oxidation hypothesis of atherosclerosis | Q40625668 | ||
| Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. | Q40694210 | ||
| Nitric oxide: a physiologic messenger | Q40797176 | ||
| Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission | Q41082098 | ||
| Gastric toxicity of antiplatelet therapy with low-dose aspirin | Q41331934 | ||
| Nitric oxide in the vasculature: physiology and pathophysiology | Q41500552 | ||
| 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats | Q41688238 | ||
| Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study | Q41696001 | ||
| A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin | Q41947362 | ||
| Guanylate cyclase activation by nitroprusside and nitrosoguanidine is related to formation of S-nitrosothiol intermediates | Q42240881 | ||
| Pranidipine enhances the action of nitric oxide released from endothelial cells | Q42482561 | ||
| Urinary NItrotyrosine Content as a Marker of Peroxynitrite-induced Tolerance to Organic NItrates | Q42483928 | ||
| Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative | Q42930380 | ||
| Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications | Q43513601 | ||
| Bradykinin metabolism in the isolated perfused rabbit heart | Q43669230 | ||
| A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection | Q43700460 | ||
| P304 | page(s) | 97-123 | |
| P577 | publication date | 2002-01-10 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Nitric oxide-releasing drugs | |
| P478 | volume | 43 |
| Q33639171 | Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. |
| Q37387617 | Application of metal coordination chemistry to explore and manipulate cell biology |
| Q33388920 | Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia |
| Q43078223 | Biological targets for isatin and its analogues: Implications for therapy. |
| Q39451162 | Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks? |
| Q92889892 | Controlled release of H2S and NO gases through CO2-stimulated anion exchange |
| Q27702646 | Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin-NO Biochemistry |
| Q36756937 | Detrimental effects of Bartonella henselae are counteracted by L-arginine and nitric oxide in human endothelial progenitor cells |
| Q46952853 | Effects of hsp90 binding inhibitors on sGC-mediated vascular relaxation |
| Q46674621 | Effects of nitric oxide and noradrenergic activation in the posterior hypothalamus on arterial pressure tolerance to nitroglycerin in rats |
| Q46222743 | Effects of nitric oxide on cell proliferation: novel insights |
| Q35209508 | Effects of slow, sustained, and rate-tunable nitric oxide donors on human aortic smooth muscle cells proliferation |
| Q30278654 | Endothelial nitric oxide synthase in the microcirculation |
| Q44519191 | Enhanced nitric oxide release/synthesis in the posterior hypothalamus during nitroglycerin tolerance in rats |
| Q37392826 | Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors |
| Q37411243 | Fluorinated xerogel-derived microelectrodes for amperometric nitric oxide sensing |
| Q34592816 | Genetic dissection of the vav2-rac1 signaling axis in vascular smooth muscle cells |
| Q36363170 | Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets |
| Q55026843 | Hemorheologic Alterations in Patients with Type 2 Diabetes Mellitus Presented with an Acute Myocardial Infarction. |
| Q44626758 | Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase |
| Q35995235 | In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors |
| Q41425045 | Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics. |
| Q42951381 | Inhibition of nitric oxide-activated guanylyl cyclase by calmodulin antagonists. |
| Q35552149 | Inorganic nitrite therapy: historical perspective and future directions. |
| Q36977563 | Inorganic/Organic Hybrid Silica Nanoparticles as a Nitric Oxide Delivery Scaffold |
| Q37829985 | Keys for unlocking photolabile metal-containing cages |
| Q37929625 | LOX-1/LOXIN: the yin/yang of atheroscleorosis |
| Q38115293 | Light-triggered nitric oxide delivery to malignant sites and infection |
| Q34515736 | Long-term combined beneficial effects of physical training and metabolic treatment on atherosclerosis in hypercholesterolemic mice |
| Q36615899 | Morphological analysis of the antimicrobial action of nitric oxide on gram-negative pathogens using atomic force microscopy |
| Q33910541 | Nitrates and nitrites in the treatment of ischemic cardiac disease |
| Q58863635 | Nitric Oxide in Vascular Damage and Regeneration |
| Q58863636 | Nitric Oxide, Oxidative Stress, Immune Response and Critical Care |
| Q36473426 | Nitric oxide and atherosclerosis: an update |
| Q37591250 | Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases |
| Q36196462 | Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential |
| Q38078367 | Nitric oxide in plants: an assessment of the current state of knowledge. |
| Q37855867 | Nitric oxide-donating materials and their potential in pharmacological applications for site-specific nitric oxide delivery |
| Q37887771 | Nitric oxide: a guardian for vascular grafts? |
| Q46856145 | Nitrite reduction mediated by the complex RuIII(EDTA). |
| Q44690690 | Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis |
| Q35801877 | Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis |
| Q35700432 | Oxidation of LDL, atherogenesis, and apoptosis |
| Q35203028 | Oxidation-sensitive mechanisms, vascular apoptosis and atherosclerosis |
| Q34259551 | Photoactive Ruthenium Nitrosyls: Effects of Light and Potential Application as NO Donors |
| Q31046745 | Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice |
| Q36703836 | Potential protective properties of a stable, slow-releasing nitric oxide donor, GEA 3175, in the lung. |
| Q36052815 | Recent developments in nitric oxide donor drugs. |
| Q42041084 | Regulation of injury-induced neurogenesis by nitric oxide. |
| Q43878443 | S-nitrosothiol tethered polymer hexagons: synthesis, characterisation and antibacterial effect |
| Q64886583 | Schiff bases containing a furoxan moiety as potential nitric oxide donors in plant tissues. |
| Q36614973 | Secondary amines containing one aromatic nitro group: preparation, nitrosation, sustained nitric oxide release, and the synergistic effects of released nitric oxide and an arginase inhibitor on vascular smooth muscle cell proliferation |
| Q44950901 | Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension |
| Q39998466 | Syntheses, structures, and photochemistry of manganese nitrosyls derived from designed Schiff base ligands: potential NO donors that can be activated by near-infrared light |
| Q57953601 | Synthetic cobalt clays for the storage and slow release of therapeutic nitric oxide |
| Q35678184 | The Role of CD36 in the Effect of Arginine in Atherosclerotic Rats |
| Q51735427 | The Unexpected Role of Calcium-Activated Potassium Channels: Limitation of NO-Induced Arterial Relaxation. |
| Q36008721 | The new nitric oxide donor cyclohexane nitrate induces vasorelaxation, hypotension, and antihypertensive effects via NO/cGMP/PKG pathway. |
| Q39198264 | The potential of stimulating nitric oxide formation in the treatment of hypertension |
| Q41808077 | The prevention of endothelial dysfunction through endothelial cell apoptosis inhibition in a hypercholesterolemic rabbit model: the effect of L-arginine supplementation |
| Q46627529 | Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol-fed rabbits |
| Q57953606 | l-Histidine-based organoclays for the storage and release of therapeutic nitric oxide |
Search more.